IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer
Journal of Cellular and Molecular Medicine · 2026-10 · 30 (20)
DOI: 10.1111/jcmm.71415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 27.10.2026. Verfasst von Hanlin Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Prostatic Neoplasms, Mitochondria, Drug Resistance, Neoplasm. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
After undergoing ADT treatment, drug resistance has emerged as a major hindrance in the treatment of prostate cancer, with enzalutamide resistance being the most notable. Our objective was to identify a new drug‐resistance mechanism present in post‐ADT‐treatment patients. Utilizing proteomic sequencing, we discovered abnormal increases in IGF1R levels. Subsequent sequencing and bioinformatic analyses showed that IGF1R could cause abnormal changes in the tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation. This phenomenon may be due to IGF1R's influence on the distribution of mitochondrial Ca 2+ and the production of reactive oxygen species (ROS). Our CHIP and dual‐luciferase experiments confirmed the regulatory relationship between IGF1R and MICU1. The fluorescent results of Ca 2+ and ROS also confirmed that IGF1R could regulate mitochondrial Ca 2+ distribution and ROS production. Our team validated the relationship between IGF1R and drug resistance through cell phenotype experiments, and explored its potential as a therapeutic target through a fa‐ci curve. Finally, we verified the effectiveness of the mechanisms we found through a xenograft assay. Our study confirms the potential for IGF1R as a clinical therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.
- Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
ORCID-Profile: Hanlin Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, H., Chen, Y., Zhou, Y., Li, Y., Gao, Y., Chen, X., Ma, Q., Zhu, S., & Wen, S. (2026). IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer. Journal of Cellular and Molecular Medicine, 30(20). https://doi.org/10.1111/jcmm.71415
Vancouver
Li H, Chen Y, Zhou Y, Li Y, Gao Y, Chen X, et al. IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer. Journal of Cellular and Molecular Medicine. 2026;30(20). doi:10.1111/jcmm.71415
BibTeX
@article{Li2026,
author = {Li, Hanlin and Chen, Yutong and Zhou, Yupeng and Li, Yang and Gao, Yukui and Chen, Xuanrong and Ma, Qianwang and Zhu, Shimiao and Wen, Simeng},
title = {IGF1R Induces ROS Formation in Mitochondria via MICU1 Leads to the Enzalutamide Resistance in Prostate Cancer},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {20},
doi = {10.1111/jcmm.71415}
}
EUVIMED